ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "New e.G.F.R. Threshold Refines HeF.pEF Diagnosis. 10/16/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded October 16, 2025. This episode summarizes 5 key cardiology studies on topics like gene therapy and Adenosine Deaminase Deficiency. Key takeaway: New e.G.F.R. Threshold Refines HeF.pEF Diagnosis..
Article Links:
Article 1: Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency. (The New England journal of medicine)
Article 2: Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT. (Journal of the American College of Cardiology)
Article 3: Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity. (Journal of the American College of Cardiology)
Article 4: Atrial cardiomyopathy: markers and outcomes. (European heart journal)
Article 5: Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/new-e-g-f-r-threshold-refines-hef-pef-diagnosis-10-16-25/
Featured Articles
Article 1: Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41092330
Summary: This study investigated the long-term safety and efficacy of gene therapy for Adenosine Deaminase Deficiency – Severe Combined Immunodeficiency, a life-threatening inborn error of immunity. Researchers treated patients with busulfan nonmyeloablative conditioning followed by transplantation of autologous C.D.34+ hematopoietic stem cells. These cells were transduced ex vivo with a lentiviral vector encoding human Adenosine Deaminase. The study aimed to establish the viability and outcomes of this advanced gene therapy approach for Adenosine Deaminase Deficiency – Severe Combined Immunodeficiency.
Article 2: Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41091084
Summary: This post hoc analysis from the ESPRIT trial aimed to characterize the benefit-harm profile of intensive blood pressure control in patients with varying degrees of frailty. Participants were categorized into nonfrail, moderately frail, and severely frail groups using the Rockwood cumulative deficit approach to calculate their baseline frailty index. The study sought to provide much-needed evidence on optimizing blood pressure management for this vulnerable population to improve clinical outcomes.
Article 3: Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41091083
Summary: This study explored the underlying role of visceral adiposity in chronic kidney disease among patients with Heart Failure with Preserved Ejection Fraction, emphasizing the need for age-adjusted renal assessment. It established that the conventional estimated glomerular filtration rate threshold of less than 60 milliliters per minute per 1.73 meters squared often overlooks age-related physiological changes. The research proposed a more appropriate age-adjusted threshold of less than 45 milliliters per minute per 1.73 meters squared for identifying intrinsic renal disease in these patients. This refined diagnostic approach clarifies the prevalence of impaired kidney function and its link to visceral adiposity in Heart Failure with Preserved Ejection Fraction.
Article 4: Atrial cardiomyopathy: markers and outcomes.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41092306
Summary: This study aimed to identify potential markers and risk factors for Atrial Cardiomyopathy and their associations with the incidence of Atrial Fibrillation, Heart Failure, and stroke. Utilizing data from the U.K. Biobank, researchers included individuals with cardiac magnetic resonance imaging and electrocardiographic information. The investigated Atrial Cardiomyopathy markers encompassed left atrial dilation, left atrial mechanical dysfunction, P-wave prolongation, and abnormal P-wave morphology. Establishing these associations could significantly enhance risk prediction and clinical management for patients susceptible to these cardiovascular complications.
Article 5: Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41091476
Summary: This prespecified substudy of the ASPREE trial investigated whether low-dose aspirin could benefit older adults with Clonal Hematopoiesis of Indeterminate Potential for the primary prevention of Cardiovascular Disease. Clonal Hematopoiesis of Indeterminate Potential is known to be associated with increased Cardiovascular Disease events and mortality, but approved therapies are lacking. The study compared daily low-dose aspirin against placebo in a double-blind, randomized clinical trial design. This research aimed to provide critical evidence for potential therapeutic interventions for Clonal Hematopoiesis of Indeterminate Potential to mitigate Cardiovascular Disease and bleeding risk.
Transcript
Today’s date is October 16, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency. This study investigated the long-term safety and efficacy of gene therapy for Adenosine Deaminase Deficiency – Severe Combined Immunodeficiency, a life-threatening inborn error of immunity. Researchers treated patients with busulfan nonmyeloablative conditioning followed by transplantation of autologous C.D.34+ hematopoietic stem cells. These cells were transduced ex vivo with a lentiviral vector encoding human Adenosine Deaminase. The study aimed to establish the viability and outcomes of this advanced gene therapy approach for Adenosine Deaminase Deficiency – Severe Combined Immunodeficiency.
Article number two. Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT. This post hoc analysis from the ESPRIT trial aimed to characterize the benefit-harm profile of intensive blood pressure control in patients with varying degrees of frailty. Participants were categorized into nonfrail, moderately frail, and severely frail groups using the Rockwood cumulative deficit approach to calculate their baseline frailty index. The study sought to provide much-needed evidence on optimizing blood pressure management for this vulnerable population to improve clinical outcomes.
Article number three. Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity. This study explored the underlying role of visceral adiposity in chronic kidney disease among patients with Heart Failure with Preserved Ejection Fraction, emphasizing the need for age-adjusted renal assessment. It established that the conventional estimated glomerular filtration rate threshold of less than 60 milliliters per minute per 1.73 meters squared often overlooks age-related physiological changes. The research proposed a more appropriate age-adjusted threshold of less than 45 milliliters per minute per 1.73 meters squared for identifying intrinsic renal disease in these patients. This refined diagnostic approach clarifies the prevalence of impaired kidney function and its link to visceral adiposity in Heart Failure with Preserved Ejection Fraction.
Article number four. Atrial cardiomyopathy: markers and outcomes. This study aimed to identify potential markers and risk factors for Atrial Cardiomyopathy and their associations with the incidence of Atrial Fibrillation, Heart Failure, and stroke. Utilizing data from the U.K. Biobank, researchers included individuals with cardiac magnetic resonance imaging and electrocardiographic information. The investigated Atrial Cardiomyopathy markers encompassed left atrial dilation, left atrial mechanical dysfunction, P-wave prolongation, and abnormal P-wave morphology. Establishing these associations could significantly enhance risk prediction and clinical management for patients susceptible to these cardiovascular complications.
Article number five. Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin. This prespecified substudy of the ASPREE trial investigated whether low-dose aspirin could benefit older adults with Clonal Hematopoiesis of Indeterminate Potential for the primary prevention of Cardiovascular Disease. Clonal Hematopoiesis of Indeterminate Potential is known to be associated with increased Cardiovascular Disease events and mortality, but approved therapies are lacking. The study compared daily low-dose aspirin against placebo in a double-blind, randomized clinical trial design. This research aimed to provide critical evidence for potential therapeutic interventions for Clonal Hematopoiesis of Indeterminate Potential to mitigate Cardiovascular Disease and bleeding risk.
Thank you for listening. Don’t forget to subscribe.
Keywords
gene therapy, Adenosine Deaminase Deficiency, ASPREE trial, Atrial Fibrillation, frailty, intensive blood pressure control, ESPRIT trial, primary prevention, Heart Failure, Heart Failure with Preserved Ejection Fraction, stroke, Severe Combined Immunodeficiency, Atrial Cardiomyopathy, renal impairment, cardiac magnetic resonance imaging, aspirin, Clonal Hematopoiesis of Indeterminate Potential, geriatric cardiology, estimated glomerular filtration rate, hematopoietic stem cells, visceral adiposity, chronic kidney disease, Cardiovascular Disease, lentiviral vector, cardiovascular risk.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post New e.G.F.R. Threshold Refines HeF.pEF Diagnosis. 10/16/25 first appeared on Cardiology Today.
Article Links:
Article 1: Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency. (The New England journal of medicine)
Article 2: Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT. (Journal of the American College of Cardiology)
Article 3: Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity. (Journal of the American College of Cardiology)
Article 4: Atrial cardiomyopathy: markers and outcomes. (European heart journal)
Article 5: Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/new-e-g-f-r-threshold-refines-hef-pef-diagnosis-10-16-25/
Featured Articles
Article 1: Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41092330
Summary: This study investigated the long-term safety and efficacy of gene therapy for Adenosine Deaminase Deficiency – Severe Combined Immunodeficiency, a life-threatening inborn error of immunity. Researchers treated patients with busulfan nonmyeloablative conditioning followed by transplantation of autologous C.D.34+ hematopoietic stem cells. These cells were transduced ex vivo with a lentiviral vector encoding human Adenosine Deaminase. The study aimed to establish the viability and outcomes of this advanced gene therapy approach for Adenosine Deaminase Deficiency – Severe Combined Immunodeficiency.
Article 2: Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41091084
Summary: This post hoc analysis from the ESPRIT trial aimed to characterize the benefit-harm profile of intensive blood pressure control in patients with varying degrees of frailty. Participants were categorized into nonfrail, moderately frail, and severely frail groups using the Rockwood cumulative deficit approach to calculate their baseline frailty index. The study sought to provide much-needed evidence on optimizing blood pressure management for this vulnerable population to improve clinical outcomes.
Article 3: Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41091083
Summary: This study explored the underlying role of visceral adiposity in chronic kidney disease among patients with Heart Failure with Preserved Ejection Fraction, emphasizing the need for age-adjusted renal assessment. It established that the conventional estimated glomerular filtration rate threshold of less than 60 milliliters per minute per 1.73 meters squared often overlooks age-related physiological changes. The research proposed a more appropriate age-adjusted threshold of less than 45 milliliters per minute per 1.73 meters squared for identifying intrinsic renal disease in these patients. This refined diagnostic approach clarifies the prevalence of impaired kidney function and its link to visceral adiposity in Heart Failure with Preserved Ejection Fraction.
Article 4: Atrial cardiomyopathy: markers and outcomes.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41092306
Summary: This study aimed to identify potential markers and risk factors for Atrial Cardiomyopathy and their associations with the incidence of Atrial Fibrillation, Heart Failure, and stroke. Utilizing data from the U.K. Biobank, researchers included individuals with cardiac magnetic resonance imaging and electrocardiographic information. The investigated Atrial Cardiomyopathy markers encompassed left atrial dilation, left atrial mechanical dysfunction, P-wave prolongation, and abnormal P-wave morphology. Establishing these associations could significantly enhance risk prediction and clinical management for patients susceptible to these cardiovascular complications.
Article 5: Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41091476
Summary: This prespecified substudy of the ASPREE trial investigated whether low-dose aspirin could benefit older adults with Clonal Hematopoiesis of Indeterminate Potential for the primary prevention of Cardiovascular Disease. Clonal Hematopoiesis of Indeterminate Potential is known to be associated with increased Cardiovascular Disease events and mortality, but approved therapies are lacking. The study compared daily low-dose aspirin against placebo in a double-blind, randomized clinical trial design. This research aimed to provide critical evidence for potential therapeutic interventions for Clonal Hematopoiesis of Indeterminate Potential to mitigate Cardiovascular Disease and bleeding risk.
Transcript
Today’s date is October 16, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency. This study investigated the long-term safety and efficacy of gene therapy for Adenosine Deaminase Deficiency – Severe Combined Immunodeficiency, a life-threatening inborn error of immunity. Researchers treated patients with busulfan nonmyeloablative conditioning followed by transplantation of autologous C.D.34+ hematopoietic stem cells. These cells were transduced ex vivo with a lentiviral vector encoding human Adenosine Deaminase. The study aimed to establish the viability and outcomes of this advanced gene therapy approach for Adenosine Deaminase Deficiency – Severe Combined Immunodeficiency.
Article number two. Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT. This post hoc analysis from the ESPRIT trial aimed to characterize the benefit-harm profile of intensive blood pressure control in patients with varying degrees of frailty. Participants were categorized into nonfrail, moderately frail, and severely frail groups using the Rockwood cumulative deficit approach to calculate their baseline frailty index. The study sought to provide much-needed evidence on optimizing blood pressure management for this vulnerable population to improve clinical outcomes.
Article number three. Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity. This study explored the underlying role of visceral adiposity in chronic kidney disease among patients with Heart Failure with Preserved Ejection Fraction, emphasizing the need for age-adjusted renal assessment. It established that the conventional estimated glomerular filtration rate threshold of less than 60 milliliters per minute per 1.73 meters squared often overlooks age-related physiological changes. The research proposed a more appropriate age-adjusted threshold of less than 45 milliliters per minute per 1.73 meters squared for identifying intrinsic renal disease in these patients. This refined diagnostic approach clarifies the prevalence of impaired kidney function and its link to visceral adiposity in Heart Failure with Preserved Ejection Fraction.
Article number four. Atrial cardiomyopathy: markers and outcomes. This study aimed to identify potential markers and risk factors for Atrial Cardiomyopathy and their associations with the incidence of Atrial Fibrillation, Heart Failure, and stroke. Utilizing data from the U.K. Biobank, researchers included individuals with cardiac magnetic resonance imaging and electrocardiographic information. The investigated Atrial Cardiomyopathy markers encompassed left atrial dilation, left atrial mechanical dysfunction, P-wave prolongation, and abnormal P-wave morphology. Establishing these associations could significantly enhance risk prediction and clinical management for patients susceptible to these cardiovascular complications.
Article number five. Clonal Hematopoiesis and Cardiovascular Disease and Bleeding Risk and the Effectiveness of Aspirin. This prespecified substudy of the ASPREE trial investigated whether low-dose aspirin could benefit older adults with Clonal Hematopoiesis of Indeterminate Potential for the primary prevention of Cardiovascular Disease. Clonal Hematopoiesis of Indeterminate Potential is known to be associated with increased Cardiovascular Disease events and mortality, but approved therapies are lacking. The study compared daily low-dose aspirin against placebo in a double-blind, randomized clinical trial design. This research aimed to provide critical evidence for potential therapeutic interventions for Clonal Hematopoiesis of Indeterminate Potential to mitigate Cardiovascular Disease and bleeding risk.
Thank you for listening. Don’t forget to subscribe.
Keywords
gene therapy, Adenosine Deaminase Deficiency, ASPREE trial, Atrial Fibrillation, frailty, intensive blood pressure control, ESPRIT trial, primary prevention, Heart Failure, Heart Failure with Preserved Ejection Fraction, stroke, Severe Combined Immunodeficiency, Atrial Cardiomyopathy, renal impairment, cardiac magnetic resonance imaging, aspirin, Clonal Hematopoiesis of Indeterminate Potential, geriatric cardiology, estimated glomerular filtration rate, hematopoietic stem cells, visceral adiposity, chronic kidney disease, Cardiovascular Disease, lentiviral vector, cardiovascular risk.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post New e.G.F.R. Threshold Refines HeF.pEF Diagnosis. 10/16/25 first appeared on Cardiology Today.
In God we trust